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transcriptomic analysis by RnA 
sequencing characterises 
malignant progression of canine 
insulinoma from normal tissue 
to metastatic disease
Y. capodanno1,2*, F. O. Buishand 2,3, L. Y. Pang2, J. Kirpensteijn3,5, J. A. Mol3, R. Elders2,4 & 
D. J. Argyle2
insulinomas (inS) are the most common human and canine functioning pancreatic neuroendocrine 
tumours. The long-term prognosis for malignant INS is poor, because micrometastases are frequently 
missed during surgery. As human and canine malignant inS share clinical and histopathological 
features, dogs have been proposed as models for INS research. Using RNA-sequencing, we conducted 
a pilot study to better understand the underlying molecular mechanisms of canine inS. normal canine 
pancreas and lymph node control tissues were compared with primary INS and INS-metastatic lymph 
nodes, revealing more than 3,000 genes differentially expressed in normal pancreas compared to 
primary INS. Only 164 genes were differentially expressed between primary INS and INS-metastatic 
lymph nodes. Hierarchical clustering analysis demonstrated similar genetic profiles in normal pancreas 
and early clinical stage primary INS, whereas late clinical stage primary INS resembled the genetic 
profile of INS-metastatic lymph nodes. These findings suggest that markers of malignant behaviour 
could be identified at the primary site of the disease. Finally, using the REACTOME pathways 
database, we revealed that an active collagen metabolism, extracellular matrix remodelling, beta-
cell differentiation and non-beta-cell trans-differentiation might cause disease progression and 
hyperinsulinism in INS, identifying major pathways worthy of future research in this currently poorly 
controlled disease.
Insulinomas (INS) are the most commonly diagnosed functioning pancreatic neuroendocrine tumours in 
humans and  dogs1,2. They are insulin-producing tumours that can arise from pancreatic beta-cells1,2. Diagnosis 
and treatment of human and canine INS can be challenging and prognosis highly variable depending on thera-
peutic  decisions3–5. Currently, surgical resection of primary localised benign INS is considered the treatment of 
choice. However, the prognosis after surgery for advanced-stage disease is still poor and adjuvant therapy options 
are  limited5,6. Thus, better therapeutic tools are urgently required.
Traditional benign versus malignant classification of these tumours is often difficult at initial diagnosis. Grade 
and stage are the major determinants of prognosis in  humans4,7. Similarly, in dogs, TNM stage, increased nuclear 
size, pleomorphism, Ki67 and DNA content are considered valuable histological features to predict the biological 
behaviour of  INS6, 8. Still, grading and staging have been so far insufficient to fully assess the degree of malig-
nancy of human and canine INS. In both humans and dogs, these tumours can have heterogeneous microscopic 
findings and the presence of metastases, mainly located in the liver, represents so far the only definitive feature 
that characterises individual tumours as  malignant3,8–11. Canine INS are considered typically malignant as they 
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develop metastases in 95% of the cases in liver/lymph  nodes9. Whereas, in humans, they are usually benign as 
only 5–16% of human INS  metastasise6,12. If malignant INS could be detected before metastasis, surgery could 
be curative. Thus, identifying specific INS biomarkers and druggable targets is crucial for earlier diagnoses and 
efficacious  treatments3–5.
Previous studies have revealed that many tumours have a unique genetic signature, often with dysregulated 
gene expression promoting tumour growth and  invasiviness13,14. Such understanding of INS is limited and there 
is an unmet need to understand the underlying transcriptomic alterations and molecular changes in order to 
advance diagnosis and  treatment4. The lack of knowledge on the genetics of INS might be partly attributed to its 
low incidence. With only four cases per million population per year, human INS have been previously studied 
mainly as part of broad studies on pancreatic neuroendocrine tumours (PNETs)15. Nonetheless, PNETs are highly 
heterogeneous tumours thus the specifics of INS oncogenesis are still poorly  understood15. In dogs, the incidence 
of INS has not been estimated yet but its rate of malignancy is higher compared to  humans9.
Comparative oncology aims to study spontaneously occurring tumours in dogs to provide interesting inform-
ative models for human cancer  research13,16–18. Since the completion of the canine genome  sequencing19, various 
RNA-sequencing (RNA-seq) studies have identified gene signature characteristics of malignancy in a variety of 
cancers occurring in dogs such as  meningioma13, mammary  carcinoma16,  melanoma20 and bladder  carcinoma18, 
providing additional information about the oncogenesis of human tumours. The close resemblance of canine 
INS to human malignant INS with regard to clinical signs, histopathology and disease progression, makes canine 
INS an interesting study model for human malignant  INS21. For instance, our recent study comparing human 
and canine INS cell lines identified the Notch pathway as a key regulator of stemness and chemoresistance both 
in vitro and in vivo, providing a rationale for focused further research on this druggable target for INS in both 
 species2.
Given the lack of global gene expression data in canine INS, the aim of this study was to develop integrative 
computational approaches to identify the mechanisms of tumourigenesis in malignant canine INS. For the first 
time, comprehensive gene expression analysis of canine INS was performed by RNA-seq to identify key molecular 
pathways in canine INS. Here, we designed a functional approach to critically analyse the transcriptomic land-
scape of canine INS and relate malignant molecular features to different clinical stages and pathological features. 
While the sample size presented herein is not large enough to generate a highly statistically powered analysis of 
canine INS, the combination of differential gene expression with pathway and network analyses unraveled some 
of the complex mechanisms in the malignant progression of canine INS that will warrant further investigation 
in larger studies.
Materials and methods
Samples and histopathology. Tumour tissue specimens were obtained from nine dogs with spontaneous 
INS by partial pancreatectomy at the Faculty of Veterinary Medicine, Utrecht University. Normal pancreas and 
mesenteric lymph node tissues were obtained for use as controls (Supplementary Table 1). No cases received 
chemotherapy or radiation prior to surgery. Each tumour tissue was fixed in 10% neutral buffered formalin for 
24 h prior to embedding in paraffin. Histopathological examination confirmed a diagnosis of canine INS in all 
cases based on the most recent adapted canine TNM staging  system6,9 and WHO grading classification (Sup-
plementary Table 2). Additional information on tissue homogenization is included in Supplementary Materials.
Animals and ethics statement. All patients had been referred to the hospital and were assessed under 
the supervision of Board-certified specialists in Small Animal Internal Medicine and/or Surgery. Dogs were 
anaesthetised during surgery under the supervision of Board-certified specialists in Anaesthesia. All diagnostic 
and surgical protocols were applied for treating patients ensuring their primary welfare according to the Animal 
Act on Veterinary Practice, as required under Dutch legislation. Written informed consent of each dog owner 
was obtained for all diagnostic procedures and for the use of anonymised clinical and pathological data for 
research purposes. Normal pancreas and mesenteric lymph node control tissues were obtained as surplus mate-
rial according to the University of Edinburgh 3R policy from four dogs that were euthanised for other unrelated 
research.
RnA‑sequencing and bioinformatic analysis. The RNA-seq reads were generated in Sanger FASTQ™ 
format using the FastQC software™ (version 0.11.5) (https ://www.bioin forma tics.babra ham.ac.uk/proje cts/
fastq c). FastQC data were trimmed from low-quality reads containing sequencing adapters and more than 
five unknown bases with Cutadapt™ (version 1.8.3). High-quality paired-end reads from the FASTQ files were 
mapped to the canine reference genome (CanFam 3.1) resulting in around 95–99% sequences mapped using 
TopHat2™ (version3.1.84) with default parameters. The output files in the compressed binary version of the 
Sequence Alignment/Map (BAM) were then assembled and counted using HTSeq™ (version 6.0.1) with mode 
"union"22. Fragments per kilobase of transcript per million mapped reads (FPKM) were imported into R™ (ver-
sion 3.3.2), and principal component analysis (PCA) was conducted with genes for which the sum of FPKMs 
of all samples was > 10. Gene counts for each sample were imported into R and differential gene expression 
was then carried out using edgeR™ (version 3.12.0). Differential expression was assessed for each gene using an 
exact test analogous to Fisher’s exact test but adapted for over-dispersed data. TMM normalization and Tagwise 
dispersion (individual dispersion for each gene) were used to adjust for abundance differences across samples, 
and differentially expressed genes (DEGs) were extracted. Genes were considered differentially expressed only 
at a P-value < 0.01 and at False Discovery Rate (FDR) < 0.05. Genes with log2-fold changes of more than 2 or less 
than − 2 were then selected to ensure that only robust changes were considered. Differentially expressed genes 
between two groups were annotated using HUGO Gene Nomenclature Committee™ (HGNC) (https ://www.
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genen ames.org). Differences in gene expression of pairwise comparisons were organised as follows: (i) normal 
pancreas against primary INS; (ii) primary INS against INS-metastatic lymph nodes; (iii) normal lymph nodes 
against INS-metastatic lymph nodes. The normalised gene counts for differentially expressed genes were ana-
lysed for hierarchical clustering analysis with the R package “heatmap2”21,23.
enrichment analysis. Enriched pathways and functional analysis were performed using both Gene set 
enrichment analysis (GSEA) (https ://softw are.broad insti tute.org/gsea/index .jsp) and Reactome (https ://www.
react ome.org).
All genes significantly differentially expressed between INS, INS-metastatic lymph nodes and normal tissues, 
were introduced into GSEA (GSEA version 2.2.2). Gene sets were created from all ensemble genes linked to the 
database of Canis Familiaris pathways and analysed with Reactome tool to have additional types of annotations 
to support pathway curation including a variety of biological processes such as signalling, metabolism, tran-
scriptional regulation, apoptosis and synaptic  transmission24. Gene sets with an FDR < 0.05 were considered as 
significantly enriched. Additional information on statistical analysis is included in Supplementary Materials.
Data visualisation. Using Python 3.7.10 (https ://www.pytho n.org/) and version 0.19.0 of the Pandas mod-
ule, the expression data from the DEG, GSEA and Reactome were read into a Pandas data frame. Box plot, smear 
plot, swarm plot, distribution curve and heatmap were generated in Python using the Matplotlib (version 2.7.1) 
and Seaborn libraries (version 0.7.1).
Quantitative real-time PCR. The levels of expression of 13 DEGs were validated using real-time reverse 
transcription polymerase chain reaction (qRT-PCR). The Platinum Syber Green qPCR Kit (Invitrogen, UK) was 
used in all qRT-PCR reactions according to the manufacturer’s instructions. Reactions were performed using the 
Stratagene MX3000P (Agilent, UK). Primer efficiency and dissociation curves were calculated with MXPro soft-
ware (Agilent, UK), specificity was assessed by agarose gel electrophoresis of the qRT-PCR products as above. 
Relative gene expression levels were obtained by normalisation to the expression levels of housekeeping genes 
[Ribosomal protein S5 (RPS5) and GAPDH). Calculations were made following the Delta Delta Ct  Method25. 
The average of the three normal samples was used for relative expression. Additional information on primers 
and cDNA extraction is included in Supplementary Materials.
Results
Quality of the samples and raw data. For each sample, RNA-seq generated between 50 and 110 million 
75 bp paired-end reads and around 95–99% of the reads were mapped to the canine genome. Using unsuper-
vised clustering, two clusters were formed: one including normal pancreatic tissues and primary INS lesions 
from patients in early clinical stage (TNM stage I and II) and a second cluster included primary INS lesions from 
patients with late clinical stage (TNM stage III and IV) and metastatic lymph nodes (Fig. 1A). Multidimensional 
analysis using Principal Component Analysis (PCA) plots showed that the normal pancreatic tissues clustered 
separately from metastatic and normal lymphatic tissues, whereas primary INS lesions had a more heterogene-
ous pattern (Fig. 1B–D). MDS analysis showed that normal pancreatic tissues clustered together and INS from 
patients in early clinical stage clustered together with normal pancreas (Fig. 1B). MDS analysis revealed that 
normal lymph nodes formed a homogeneous cluster fully separate from INS-metastatic lymph nodes (Fig. 1C). 
Finally, MDS analysis showed that the distribution of primary INS in early clinical stage clustered separately 
from INS-metastatic lymph nodes (Fig. 1D). Whereas, primary INS lesions derived from patients in late clini-
cal stage disease had low gene expression variance when compared with the metastatic lymph nodes (Fig. 1D).
Differential expression analysis of primary INS. Paired statistical tests (P-value < 0.01; FDR < 0.05) 
revealed 3,212 genes to be differentially expressed between primary INS and normal pancreas. Violin plot 
(Fig. 2A), smear plots and volcano plots show the distribution of DEG in the up- or downregulated sections 
based on their counts and FDR (Supplementary Fig. 1A,B). When only looking at log2-fold changes of more 
than 2 or less than − 2, 1,900 features remained (1,590 upregulated genes and 310 downregulated genes). Based 
on the expression levels of DEGs, we performed hierarchical clustering analysis using heatmap functions and 
revealed distinct clustering of INS tissues in advanced clinical stage (TNM stage II to IV) compared with INS 
TNM stage I and normal pancreatic tissues respectively (Fig. 2B). Further unsupervised matrix clustering con-
firmed these findings (Fig. 2C).
When interrogating the 100 most DEG, data revealed many of the upregulated genes were involved in beta-
cell differentiation such as Paired homeobox 4 (PAX4), NK Homeobox 2 (NKX2) and Insulinoma associated 1 
(INSM1), insulin secretion [tetraspanin1 (TSPAN1), glucokinase (GCK), insulin (INS) and Nestin (NESTIN)] and 
in pancreatic development such as Hes-related family BHLH transcription factor 1 (HEY1), pancreatic duodenal 
homeobox 1 (PDX1) and SRY-Homeobox 17 (SOX17) (Table 1) (Supplementary Fig. 2). Of interest, well-known 
pancreatic neuroendocrine markers such as Chromogranin B and Secretogranin II and also alpha and ductal cell-
related genes such GCGR , SERPINA1 and PAPPA2 were also among the top 100 DEG in primary INS (Table 1).
To investigate global trends in the DEG signature, GSEA was performed. Gene sets with significant enrich-
ment included 26 down- and 60 upregulated functions. To further consider the biological significance of these 
data, they were analysed with the Reactome pathway database which revealed 30 upregulated and 15 down-
regulated pathways. Most of the upregulated pathways were related to five functional clusters: beta cell fate, 
insulin secretion/membrane polarization, cell cycling, extracellular matrix organization and collagen remodelling 
(Fig. 2D). Whereas, about 50% of the downregulated pathways were associated with ribosomes, transcription, 
and translation of proteins (Fig. 2E).
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Differential expression analysis of metastatic INS. RNA-seq data revealed 6,349 DEG between nor-
mal and INS-metastatic lymph nodes (Supplementary Fig. 3A,B). According to hierarchical clustering analysis 
using heatmap function (Supp Fig. 3C) and matrix correlation (Supplementary Fig. 3D) normal lymph nodes 
and INS-metastatic lymph nodes formed two separate clusters with different gene expression profiles. These data 
confirmed that the INS-metastatic lymph nodes had a different gene expression profile compared to the normal 
lymph nodes.
When comparing primary INS tissues and INS-metastatic lymph nodes 164 DEGs were identified with 
log2-fold changes or more (80 genes upregulated and 84 downregulated). Violin plot (Fig. 3A), smear plots and 
volcano plots show the distribution of DEG in the up- or down regulated sections based on their counts and FDR 
(Supplementary Fig. 1C,D). Heatmap analysis showed two separate clusters, one including INS-metastatic lymph 
nodes and primary lesions derived from patients with TNM disease stage IV and high-grade disease (Grade 
2) and the second including primary INS TNM stage I–III samples and low-grade disease (Grade 1) (Fig. 3B). 
Unsupervised matrix clustering of the coding profiles showed that primary lesions derived from patients with 
metastatic disease (TNM stage III and IV) clustered together with the metastatic lymph nodes (Fig. 3C).
Relative expression variances showed that acinar-related genes were downregulated in metastatic lesions such 
as pancreatic lipase (PNLIP) and chymotrypsinogen2 (CTBR2) together with different transcripts regulating 
tight junctions such as claudin 10 (CLDN10), claudin 19 (CLDN19). Whereas, cell adhesion markers previously 
related to oncogenesis, such as adhesion molecule with Ig like domain 2 (AMIGO2) and von Willebrand fac-
tor A domain-containing 5 A (VWA5A) (Table 2), were upregulated together with small cytokines involved in 
inflammation, such as C-X-C motif chemokine receptor 5 (CXCR5) and chemokine (C-X-C motif) ligand 13 
(CCL13) (Table 2). The aforementioned genes showed different levels of interactions (Supplementary Fig. 4). 
Table 1.  Top most differentially expressed genes in primary insulinoma vs normal pancreas. In bold genes 
used for validation with qRT-PCR.
Gene Gene symbol Log2FC P-value FDR Role
Pancreatic duodenal homeobox 1 PDX1 2.13 0.0001 0.003
Beta-cell differentiation
Paired homeobox 4 PAX4 6.23 3.32E−09 3.92E−06
Insulinoma associated 1 INSM1 5.021 3.40E−07 5.17E−05
NK2 homeobox 2 NKX2 5.32 3.40E−09 3.92E−09
Nestin NES 2.53 0.0001 0.003
Delta/notch-like EGF repeating contain-
ing ligand DNER 4.41 3.05E−07 4.83E−05
Pancreatic ontogeny
SRY-box 17 SOX17 2.20 0.009 0.04
SRY-box 18 SOX18 2.89 0.003 0.02
Hes-related family BHLH transcription 
factor 1 HEY1 2.46 0.0009 0.01
Glutathione peroxidase 3 GPX3 4.73 3.91E−08 1.42E−05
Glucose metabolism
Glucokinase GCK 5.37 3.13E−08 1.23E−05
Solute carrier 38 family 8 SCL38F8 9.65 9.63E−08 2.35E−08
Insulin secretion
Calcium bynding protein 1 CA1 5.09 1.66E−08 8.82E−06
Potassium voltage-gated channel subfam-
ily H member 2 KCNH2 5.47 7.40E−09 6.63E−06
Otoferlin (calcium sensor) OTOF 5.56 9.07E−08 2.32E−05
Tetraspanin 1 TSPAN1 5.46 5.95E−08 1.97E−05
Insulin production
Insulin-degrading enzyme IDE − 2.29 7.33E−06 0.0003
Insulin growth factor receptor 2 IGF2 4.33 9.30E−06 0.0004
Insulin like 6 INS 3.21 0.007 0.04
Insulin receptor INSR − 2.62 1.00E−07 2.35E−05
Islet amyloyde polyptide IAPP 4.37 2.32E−06 0.0001 Amyloid deposition
Chromogranin B CHGB 4.58 1.33E−07 2.79E−05
Pancreatic neuroendocrine tumours 
markersSecretogranin II SCG2 4.97 1.11E−07 2.49E−05
Synapsin I SYN1 5.59 7.87E−09 6.68E−06
Alpha amylase AMY1A − 7.63 8.93E−09 6.88E−06 Pancreatic exocrine marker
Pseudopodium-enriched atypical kinase 1 PEAK1 − 3.09 6.10E−09 5.78E−06
Glucose metabolism
Solute carrier 7 family 1 SLC7A1 − 3.03 2.37E−07 4.13E−05
Serpin inhibitor peptidase clade I SERPINA1 3.93 2.08E−07 3.87E−05
Ductal cell markers
Pappalysin 2 PAPPA2 5.40 1.00E−07 2.35E−05
Glucagon receptor GCGR 7.63 3.54E−10 1.30E−06 Alpha cell marker
Integrin-alpha 2 (CD49b) ITA2 − 3.45 2.76E−08 1.17E−05 Cell adhesion
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Of interest, we revealed that VWA5A, AMIGO2 and CCL13 were commonly dysregulated in all three pairwise 
analyses performed in this study (Supplementary Fig. 5 and Supplementary Table 4).
Finally, pathway analysis with the GSEA tool through the Reactome pathway database selected on the FDR 
value, revealed 14 pathways in the downregulated set associated with translation and stress induced response 
(glutathione conjugation) (Fig. 3D), whereas the PI3K pathway was upregulated.
qRT-PCR validation of RNA-seq analysis. Expression of thirteen genes was quantified with qRT-PCR 
to investigate the validity of the results of the RNA-seq transcriptome analysis, using the same RNA template 
material. Changes in mRNA levels assessed by qRT-PCR were concordant with those observed by RNA-seq 
analysis. Eight genes were upregulated in the primary INS compared with normal pancreatic tissues including 
PDX1, INSM1, PAX4, NKX2, SOX17, IAPP, NESTIN and INS. Four genes were significantly downregulated in 
primary INS compared to metastatic lymph nodes including PNLIP, CTRB2, PA and KRT19. Two endogenous 
control genes that were expressed in all samples, RSP5 and GADPH were combined to serve as the internal 
control for each sample. The qRT-PCR results were congruent with the RNA-seq global profiling, supporting the 
validity of the RNA-seq analyses (Fig. 4).
Discussion
In this study, we applied an in-depth transcriptome sequencing approach to identify gene expression character-
istics of canine INS and to gain new insight into the development of this tumour in dogs.
To the authors’ knowledge, an RNA-seq approach has never before been used to study canine INS, whereas 
recent studies have examined the genetics of human INS in the much broader context of  PNETs15. Therefore, not 
much is known about the genetics of this unique type of tumour. Considering the higher frequency of malignant 
behaviour in canine INS compared to human INS, our data might offer a model for the further characterisation 
of the malignant transcriptomic signature of human  INS2.
Our RNA-seq analysis study detected 3,212 DEGs between normal pancreas and primary INS. Unsupervised 
clustering of these DEGs showed that normal pancreatic tissues clustered with primary INS lesions from patients 
bearing early stage INS (TNM stage I), and clustered separately from primary INS lesions from patients bearing 
advanced stage disease (TNM stage II–IV). When comparing primary INS with INS-metastatic lymph nodes, 
only 164 DEG were identified, suggesting less transcriptomic variances between these  tissues21. Unsupervised 
clustering showed that primary INS from patients with high-grade INS (Grade 2) clustered together with the 
INS-metastatic lymph nodes. Additionally, unsupervised clustering of normal lymph nodes and INS-metastatic 
lymph nodes confirmed that the INS-metastatic lymph nodes had a gene signature more similar to the primary 
INS tissues than to that of normal lymph  nodes21.
Overall, these data show that early stage/low-grade INS might have a distinct gene expression pattern com-
pared to late stage/high-grade INS. Whereas, late stage/high-grade INS resemble INS-metastatic lymph nodes’ 
gene profile. Consistent with our data, previous microarray analyses have shown that primary canine INS lesions 
with high metastatic potential clustered together with their corresponding lymph node and liver metastases, 
identifying a homogeneous gene  signature9. Thus, we hypothesise that a specific transcriptomic signature related 
to a primary mass with high metastatic potential might already belong to primary INS lesions as previously seen 
in a variety of human cancers including  colorectal26,27, prostate  cancer28 and non-functioning  PNETs29. Given 
that INS metastases are not easy to detect during  surgery6, these findings could help to identify those primary 
INS lesions with a high risk of metastasis based on gene expression.
Table 2.  Top most differentially expressed genes in metastatic lymph nodes vs primary insulinomas. In bold 
genes used for validation with qRT-PCR.
Gene Gene symbol Log2FC P-value FDR Role
Chymotrypsinogen 2 CTRB2 − 8.72137 0.000178 0.033077
Exocrine markers
Pancreatic lipase PNLIP − 8.54384 0.000343 0.04279
Pancreatic amylase AMY2A − 4.79146 0.000451 0.047458
Chymotrypsin-like CTRC − 8.86682 0.000427 0.046186
Cytocherathin 19 KRT19 − 8.38703 0.000115 0.027504
Cell adhesion
Matrix metallopeptidase 23B MMP23B − 4.53596 0.000367 0.044113
Adhesion molecule with Ig like domain 2 AMIGO2 5.298697 8.31E−05 0.02421
Von Willebrand factor A domain contain 5A VWF5A 8.34709 3.41E−06 0.026348
Serpin peptidase inhibitor, clade I, member 2 SERPINA1 − 8.809 0.00035 0.043207
Serine peptidase activity
Serine peptidase inhibitor, Kazal type 1 SPINK1 − 8.55149 0.000344 0.04279
Claudin 10 CLDN10 − 7.19894 0.000195 0.034024
Cell junctions
Claudin 19 CLDN19 − 7.69326 2.40E−05 0.012854
Gap junction protein beta 1 GAPJB1 5.41801 0.000178 0.033077
Adhesion G protein-coupled receptor F4 ADGRF4 7.871758 0.000116 0.027504
C-X-C motif chemokine receptor 5 CXCR5 3.178023 0.000205 0.03415
Inflammation
Chemokine (C-X-C motif) ligand 13 CCL13 4.853102 8.30E−05 0.02421
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Amongst the 100 most DEGs between normal pancreatic tissues and INS, we identified beta-cell-specific 
transcription factors such as PDX1, INSM1, NKX2 and PAX4. Together these genes are key regulators of cell 
fate in beta-cells and orchestrate a network of genes that govern beta-cell expansion and survival under physi-
ological and pathological  conditions30–32. Beside beta-cell genes, our data showed that alpha and ductal cell genes 
such as GCGR, SERPINA1, PAPPA2 were amongst the upregulated genes in primary INS. These data suggest 
that the canine INS population is more heterogeneous than previously thought. Previous studies showed that 
tumour-initiating cells in INS might be of non-islet origin and might derive from ductal and acinar  cells33,34. 
For instance, in a zebrafish model, trans-differentiation from alpha cells to beta cells has been identified as a 
regenerative mechanism of the islets when stress conditions occur independently from glycogen and glucose 
 alteration35. Based on these data, we suggest in our model that concurrent overgrowth of beta-cells and trans-
differentiation from alpha and ductal cells to beta insulin-producing cells could be involved in tumourigenesis 
of canine  INS21 (Fig. 5).
Figure 1.  Clustering of normal pancreatic tissues, lymph nodes, primary INS lesions and metastatic lymph 
nodes. Unsupervised hierarchical clustering based on matrix correlation (A) shows clustering of normal 
pancreatic and lymphatic tissues, primary INS lesions in different TNM stages and metastases. The colour bar 
indicates the matrix distance (0 = the closest and 1 = the farthest). Multidimensional scaling with PCA plots on 
two dimensions between normal pancreas and primary INS (B), normal lymph nodes and metastatic lymph 
nodes (C), and primary INS and metastatic lymph nodes (D) shows controls cluster separately from the tumour 
samples. Panc = Normal pancreas; INS = Insulinoma TNM stage III–IV; INSp = Insulinoma TNM I stage; 
INSs = Insulinoma TNM stage II; M = Metastases; Ln = Normal ymph node. Patients’ TNM stage is described in 
Supplementary Table 1.
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Combined analysis with GSEA and Reactome tools also revealed that upregulated pathways in primary INS 
compared to normal pancreas were related to three major functional clusters: beta-cell fate, insulin secretion/
membrane polarisation and extracellular matrix organisation. Disruptions in beta-cell differentiation have been 
previously identified in human  INS1,36, nonetheless the mechanisms causing hyperinsulinism have not yet been 
elucidated. Mutations of the membrane polarisation in beta-cells could cause the failure of glucose-dependent 
insulin secretion and these mutations have been related to human  diabetes37. Our data showed that potas-
sium channel and sodium channel-related functions were amongst the upregulated functions in primary INS. 
Downregulated pathways in primary INS included the regulation of pyruvate activity and the Smad-signalling 
pathways. Pyruvate is a key enzyme in glycolysis and in the glucose-related insulin  response38. Smad-BMP 
signalling prevented beta-cell differentiation in stem cells in both a zebrafish and a mouse model, and repressed 
insulin production in islet beta-cell lines and isolated murine  islets39. These data suggest that the disruption 
of conductance and membrane polarisation within the cells combined with decrease of the capacity of cells to 
regulate glucose-related insulin response might be causing loss of normal glucose/insulin homeostasis in INS. 
These mechanisms together could be the main cause of hyperinsulinism from the early onset of primary INS 
lesions in  dogs21 (Fig. 5).
Figure 2.  Differential gene expression (DEG) and Reactome pathways analysis between normal pancreatic 
tissue and primary insulinoma tissue. Violin chart plot (A) based on log2FC displays the DEG highlighting the 
set of altered genes and shows the distribution in the up and down set with log2FC <  − 2 and > 2. Based on the 
3,000 differentially expressed genes normal pancreas and primary INS were clustered using heatmap2 function 
(B) and matrix correlation (C). Reactome analysis of the enriched function according to Gene set enrichment 
analysis showed the enriched pathways in the upregulated (D) and the downregulated (E) set selected on the 
False discovery rate (FDR < 0.05). Where the size represents the number of genes in the pathway and the Rank 
at Max shows the presence of these genes between the top up- or downregulated. Patients’ stage is described in 
Supplementary Table 1.
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However, different mechanisms seem to be involved in the metastatic progression of malignant canine INS. 
When comparing primary INS to metastatic lymph nodes we revealed 164 differentially expressed  genes21. In 
particular, genes related to acinar exocrine pancreatic enzymes such as PNLIP and CTRB1, and PA together with 
KRT19, a marker of ductal cells and SERPINA1, a marker of alpha-cells, were downregulated in the metastatic 
lymph nodes. These data confirmed the findings of the previous microarray analysis performed on canine INS 
where these genes were significantly downregulated in the metastatic INS  lesions9. Two subgroups of extracel-
lular matrix (ECM) proteins were differentially expressed in the metastatic lymph nodes. The first subgroup 
included two upregulated core matrisome proteins, AMIGO2 and VWA5A. VWA5A plays functional roles in 
cancer progression and in the angiogenic switch of different tumour types including  INS40. The cell adhesion 
marker AMIGO2 has been previously highlighted as a specific neuroendocrine  marker41 and is involved in liver 
 metastasis42. The second subgroup included tight junctions-associated proteins that were downregulated such 
as CLAUDIN 10 and 19. Downregulation of claudins causes loss of cell adhesion, which in cancer is an essential 
step towards metastatic  spread21, 43. These results suggested that changes of ECM-cell interaction and collagen-
cell interactions might be highly significant during progression of the malignant disease as previously seen in 
an INS mouse  model40 but not yet in human INS expression  studies1, 44.
Figure 3.  Differential gene expression (DEG) and Reactome pathways analysis between primary insulinoma 
(INS) tissues and INS-metastatic lymph node tissue. Violin chart plot (A) based on log2FC display the DEG 
highlighting the set of altered genes and the distribution in the up and down set with log2FC <  − 2 and > 2. 
Based on the 164 differentially expressed genes primary INS and metastatic lymph nodes were clustered using 
heatmap2 function (B) and matrix correlation (C). Reactome analysis of the enriched function according to 
Gene set enrichment analysis shows the enriched pathways in the downregulated (D) set selected based on the 
False discovery rate (FDR < 0.05), where the size represents the number of genes in the pathway and the Rank 
at Max shows the presence of these genes between the top up- or downregulated. Patients’ stage is described in 
Supplementary Table 1.
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Consistent with these data, comparisons of the three pairwise genetic analysis revealed that AMIGO2 and 
VWA5A were upregulated in both primary and metastatic lesions, suggesting that cell adhesion might play a role 
in canine INS malignant progression. Finally, GSEA and Reactome pathway analysis showed that the remodelling 
of the ECM was amongst the altered pathways between primary INS and INS-metastatic lymph nodes. Addi-
tionally, the PI3K pathway, a well-known oncogenic mechanism in human  PNETs45, was upregulated in canine 
INS metastatic lesions. Thus, in our model, we suggest that the dysregulation in ECM remodelling might be an 
active contributor to driving INS cancer progression, leading to downstream activation of intracellular kinase 
signalling pathways, such as PI3K. These mechanisms might contribute to generate a fibrotic pro-tumourigenic 
microenvironment causing collagen modifications and further facilitating the invasion of primary tumour cells 
into the surrounding tissue (Fig. 5). For instance, recent studies have shown that fibrosis and infiltrative growth 
pattern are significant risk factors for human PNET  recurrence46, thus underlining the critical role of the crosstalk 
between cancer cells and the tumour stroma during PNET tumour progression. Future studies on the whole 
spectrum of interactions between cancer cells and variable INS tumour stroma components will be needed to 
fully unravel the role of the mechanisms herein identified in canine INS tumour progression.
In summary, in the current study, we designed a functional approach to critically analyse the transcriptomic 
landscape of canine INS and relate different malignant molecular subtypes to both clinical staging and pathologi-
cal grading. Considering the lack of a system to fully characterise INS malignant potential, these findings could 
significantly help to stratify patients and treat them according to the features of their disease. Additionally, for 
the first time, we described the changes occurring at the molecular level and the pathways involved from healthy 
tissues to metastatic disease in canine INS. Our data revealed a number of interesting over- and under-expressed 
genes, providing rational targets for novel therapeutics and early-stage diagnostics for canine patients. Specifi-
cally, we hypothesise that canine INS undergo a complex transformation from the non-neoplastic tissue, that 
actively promotes collagen metabolism, extracellular matrix remodelling, beta-cell differentiation and disruption 
of membrane polarisation. These observations provide additional clues to study the mechanisms of hyperinsu-
linism and metastases often occurring in malignant canine INS. Detailed molecular mechanistic studies would 
determine the causal relationships of the differentially expressed genes herein identified and INS oncogenesis. 
Additionally, this model could be easily applied in the future in a large case series to analyse the spatiotemporal 
axis from disease onset to metastatic disease. Still, these findings elucidate further the process of pathological 
change from healthy to diseased tissues in canine INS and would support future investigations on druggable 
targets and explore the translational potential of studying highly malignant subtypes in human and canine INS.
Figure 4.  qRT-PCR validation of 13 genes comparing normal pancreatic tissues (NP) and primary insulinoma 
(PI) and PI and metastatic lymph nodes (ML). The average of three normal samples was used for relative 
expression (reference delta Ct). logFC = log fold change.
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Data availability
The sequencing data used in this study have been deposited in the Sequencing Read Archive with accession 
number PRJNA574196 at the following link (https ://www.ncbi.nlm.nih.gov/sra/PRJNA 57419 6). The differential 
gene expression analysis and functional analysis have been deposited in Figshare repository at the following DOI 
(https ://doi.org/10.6084/m9.figsh are.c.46861 07).
Received: 31 October 2019; Accepted: 22 June 2020
References
 1. Wang, X. C. et al. Gene expression profiling in human insulinoma tissue: Genes involved in the insulin secretion pathway and 
cloning of novel full-length cDNAs. Endocr. Relat. Cancer 11, 295–303 (2004).
 2. Capodanno, Y. et al. Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells. Endocr. Relat. Cancer 25, 1–14 
(2017).
 3. Baudin, E. et al. Malignant insulinoma: Recommendations for workup and treatment. Press. Med. 43, 645–659 (2014).
 4. Buishand, F. O. et al. Evaluation of prognostic indicators using validated canine insulinoma tissue microarrays. Vet. J. 201, 57–63 
(2014).
Figure 5.  Hypothesised model of canine insulinomas tumour progression. We hypothesise two major changes 
occur during canine INS oncogenesis towards malignant progression. Early change: upregulation of beta-cell 
differentiation increases cell proliferation in the normal islets. Then dysregulation of membrane polarisation of 
cells disrupts the normal insulin homeostasis. Downregulation of Smad-signalling and pyruvate kinase activity 
further dysregulate the glucose-dependent insulin production. Increased numbers of islet cells and elevated 
insulin secretion induce a stressful microenvironment that cause trans differentiation of non-beta cells to 
beta-cells. In this scenario, cell–cell interactions diminish and cells acquire invasive capability. Late change: cell 
growth in the absence of cell–cell interaction causes loss of their cell adhesion and increase in the extracellular 
matrix remodelling to facilitate migration towards the lymphatic vessel. An increased cell survival mechanism 
(PI3K signalling) and increased inflammation (chemokine signalling) push the cells to disrupt the lymphatic 
vessel and metastasise to the adjacent lymph nodes. These mechanisms together might be responsible for 
promoting metastatic spread in INS.
11
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11581  | https://doi.org/10.1038/s41598-020-68507-z
www.nature.com/scientificreports/
 5. Wouters, E. G. H., Buishand, F. O., Kik, M. & Kirpensteijn, J. Use of a bipolar vessel-sealing device in resection of canine insulinoma. 
J. Small Anim. Pract. 52, 139–145 (2011).
 6. Buishand, F. O., Kik, M. & Kirpensteijn, J. Evaluation of clinico-pathological criteria and the Ki67 index as prognostic indicators 
in canine insulinoma. Vet. J. 185, 62–67 (2010).
 7. Ro, C., Chai, W., Yu, V. E. & Yu, R. Pancreatic neuroendocrine tumors: Biology, diagnosis, and treatment. Chin. J. Cancer 32, 
312–324 (2013).
 8. Jutting, U. et al. Canine neuroendocrine tumors of the pancreas: Image analysis techniques for the discrimination versus non-
metastatic tumors of metastatic. Vet. Pathol. 145, 138–145 (1997).
 9. Buishand, F. O. et al. Gene expression profiling of primary canine insulinomas and their metastases. Vet. J. 197, 192–197 (2013).
 10. Ehehalt, F., Saeger, H. D., Schmidt, C. M., Tzmann, R. G. & Grützmann, R. Neuroendocrine tumors of the pancreas learning 
objectives. Oncologist 140014, 456–467 (2009).
 11. Halfdanarson, T. R., Rubin, J., Farnell, M. B., Grant, C. S. & Petersen, G. M. Pancreatic endocrine neoplasms: Epidemiology and 
prognosis of pancreatic endocrine tumors. Endocr. Relat. Cancer 15, 409–427 (2008).
 12. Jonkers, Y. M. H. et al. Molecular parameters associated with insulinoma progression: Chromosomal instability versus p53 and 
CK19 status. Cytogenet. Genome Res. 115, 289–297 (2006).
 13. Grenier, J. K., Foureman, P. A., Sloma, E. A. & Miller, A. D. RNA-seq transcriptome analysis of formalin fixed, paraffin-embedded 
canine meningioma. PLoS ONE 12, 1–17 (2017).
 14. Morris, J. S. Genomic and proteomic profiling for cancer diagnosis in dogs. Vet. J. 215, 101–109 (2016).
 15. Mafficini, A. & Scarpa, A. Genomic landscape of pancreatic neuroendocrine tumours: The International Cancer Genome Con-
sortium. J. Endocrinol. 236, R161–R167 (2018).
 16. Lee, K., Park, H., Son, K., Shin, T. & Cho, J. Transcriptome signatures of canine mammary gland tumors and its comparison to 
human breast cancers. 1–19 (2018). https ://doi.org/10.3390/cance rs100 90317 
 17. Frampton, D. et al. Molecular signatures of regression of the canine transmissible venereal tumor article molecular signatures of 
regression of the canine transmissible venereal tumor. Cancer Cell 33, 620-633.e6 (2018).
 18. Maeda, S. et al. Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq. BMC 
Cancer 18, 1–11 (2018).
 19. Gordon, I., Paoloni, M., Mazcko, C. & Khanna, C. The comparative oncology trials consortium: Using spontaneously occurring 
cancers in dogs to inform the cancer drug development pathway. PLoS Med. 6, 2–6 (2009).
 20. Brachelente, C. et al. Transcriptome analysis of canine cutaneous melanoma and melanocytoma reveals a modulation of genes 
regulating extracellular matrix metabolism and cell cycle. Sci. Rep. 7, 1–12 (2017).
 21. Capodanno, Y. Identifying Therapeutic Implications of Cancer Stem cells in Human and Canine Insulinoma (Univ. Edinburgh, 
Edinburgh, 2018).
 22. Anders, S., Pyl, P. T. & Huber, W. Genome analysis HTSeq—A Python framework to work with high-throughput sequencing data. 
Bioinformatics 31, 166–169 (2015).
 23. D’haeseleer, P. How does gene expression clustering work?. Nat. Biotechnol. 23, 1499–1501 (2005).
 24. Croft, D. et al. Reactome: A database of reactions, pathways and biological processes. Nucleic Acid Res. 39, 691–697 (2011).
 25. Pfaffl, M. W. Relative quantification. Real-time PCR (Dorak T. Edition), 63–82 (2004).
 26. Kim, K.-P. et al. Paired primary and metastatic tumor analysis of somatic mutations in synchronous and metachronous colorectal 
cancer. Cancer Res. Treat. 49, 161–167 (2017).
 27. Koehler, A. et al. Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopatho-
logical stage. J. Pathol. 204, 65–74. https ://doi.org/10.1002/path.1606 (2004).
 28. Kneppers, J. et al. Frequent clonal relations between metastases and non-index prostate cancer lesions. JCI Insight 4, e124756 
(2019).
 29. Capurso, G. et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential 
novel markers and therapeutic targets. Endocr. Relat. Cancer. 13, 541–558. https ://doi.org/10.1677/erc.1.01153 (2006).
 30. Lima, M. J. et al. Generation of functional beta-like cells from human exocrine pancreas. PLoS ONE 11, 1–19 (2016).
 31. Hermann, G., Konukiewitz, B., Schmitt, A., Perren, A. & Klöppel, G. Hormonally defined pancreatic and duodenal neuroendocrine 
tumors differ in their transcription factor signatures: Expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch. 459, 147–154 
(2011).
 32. Lan, M. S. & Breslin, M. B. Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine dif-
ferentiation. FASEB J. 23, 2024–2033 (2009).
 33. Vortmeyer, A. O., Huang, S., Lubensky, I. & Zhuang, Z. Non-islet origin of pancreatic islet cell tumors. J. Clin. Endocrinol. Metab. 
89, 1934–1938 (2004).
 34. Regitnig, P., Spuller, E. & Denk, H. Insulinoma of the pancreas with insular–ductular differentiation in its liver metastasis—Indica-
tion of a common stem-cell origin of the exocrine and endocrine components. Virchows Arch. 438, 624–628 (2001).
 35. Ye, L., Robertson, M. A., Hesselson, D., Stainier, D. Y. R. & Anderson, R. M. glucagon is essential for alpha cell transdifferentiation 
and beta cell neogenesis. Development 142, 1407–1417. https ://doi.org/10.1242/dev.11791 1 (2015).
 36. Wang, H. et al. Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas. 
Nat. Commun. 8, 767–781. https ://doi.org/10.1038/s4146 7-017-00992 --9 (2017).
 37. Koster, J. C., Permutt, M. A. & Nichols, C. G. Diabetes and insulin secretion. Diabetes 54, 3065–3072 (2005).
 38. Zhang, S., Hulver, M. W., Mcmillan, R. P., Cline, M. A. & Gilbert, E. R. The pivotal role of pyruvate dehydrogenase kinases in 
metabolic flexibility. Nutr. Metab. 11, 1–9 (2014).
 39. Ripoche, D. et al. ActivinB is induced in insulinoma to promote tumor plasticity through a β-cell-induced dedifferentiation. Mol. 
Cell Biol. 36, 756–764 (2016).
 40. Naba, A., Clause, K. R., Mani, D. R., Carr, S. A. & Hynes, R. O. Quantitative proteomic profiling of the extracellular matrix of 
pancreatic islets during the angiogenic switch and insulinoma progression. Sci. Rep. 7, 1–12. https ://doi.org/10.1038/srep4 0495 
(2017).
 41. Rabenau, K. E. et al. DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocar-
cinoma: Effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity. Oncogene 23, 5056–5067. https ://
doi.org/10.1038/sj.onc.12076 81 (2004).
 42. Kanda, Y., Osaki, M., Onuma, K. & Sonoda, A. Amigo2-upregulation in tumour cells facilitates their attachment to liver endothelial 
cells resulting in liver metastases. Nat. Publ. Gr. 7, 1–13. https ://doi.org/10.1038/srep4 3567 (2017).
 43. Zeng, Z., Que, T., Zhang, J. & Hu, Y. A study exploring critical pathways in clear cell renal cell carcinoma. Exp. Ther. Med. 7, 
121–130. https ://doi.org/10.3892/etm.2013.1392 (2014).
 44. Wang, H. et al. Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas. 
Nat. Commun. 8, 1–14 (2017).
 45. Nölting, S. et al. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from 
multiple cell line models. PLoS ONE 12, 1–29 (2017).
 46. Chatterjee, D. et al. Intratumoral fibrosis and tumor growth pattern as prognostic factors in optimally resected pancreatic an 
analysis of 168 cases. Pancreas 49, 255–260 (2020).
12
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11581  | https://doi.org/10.1038/s41598-020-68507-z
www.nature.com/scientificreports/
Acknowledgements
The authors would like to thank Prof. Laura Blackwood, Dr. Shareen Forbes, Dr. Mark Woodcock, Dr. Anna 
Sanchez Calle, Dr. Roberta Carloni and Dr. Gabriele Piconi for stimulating interesting discussion during the 
final stage of the project. Finally, the authors are grateful to Dr. Martin Jones and Mrs Rhona Muirhead for 
the technical support. YC acknowledges the financial support for this project of the University of Edinburgh 
PhD studentship (G338Q5). DJA, FOB, LYP, JAM, JK acknowledge the financial support of the Morris Animal 
Foundation (D14CA-503).
Author contributions
Y.C., D.J.A., R.E., L.Y.P., F.O.B., J.K., J.A.M. conceived the study. Y.C., D.J.A., R.E., L.Y.P. designed the study. J.K. 
and F.O.B. treated the patients and performed the surgery. Y.C. and R.E. collected the samples. Y.C. acquired, 
analysed and interpreted the data, prepared the pictures and tables. Y.C. and R.E. wrote the final draft of the 
manuscript. All authors reviewed and approved the final manuscript herein submitted.
competing interests 
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-68507 -z.
Correspondence and requests for materials should be addressed to Y.C.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this license, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
